Conferences - Results from #11720

AUA 2011 - Androgen independent, tumor-reinitiating cells are selected by androgen deprivation in models of androgen dependent prostate cancer - Session Highlights May 16, 2011

AUA 2011 - Andrographolide targets AR pathway in castration-resistant prostate cancer - Session Highlights May 16, 2011

AUA 2011 - Association of the number of lymph nodes (LN) removed at radical prostatectomy with all-cause (ACM) and prostate cancer-specific mortality (PCSM) - Session Highlights May 16, 2011

AUA 2011 - Benefit of denosumab therapy in patients with bone metastases from castrate resistant prostate cancer: A number-needed-to-treat (NNT) analysis - Session Highlights May 16, 2011

AUA 2011 - Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors - Session Highlights May 16, 2011

AUA 2011 - Clusterin antisense inhibitor OGX-011 synergizes activity of second generation anti-androgen, MDV3100, in castrate resistant prostate cancer model - Session Highlights May 16, 2011

AUA 2011 - Consistency of tumor position on repeat prostate biopsy in men on active surveillance for prostate cancer-implications for hemiablation - Session Highlights May 16, 2011

AUA 2011 - Differential expression of RANKL and osteoprotegerin in patients with clinically localized prostate cancer - Session Highlights May 16, 2011

AUA 2011 - Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality - Session Highlights May 16, 2011

AUA 2011 - Implications of surgical margin status on prostate cancer-specific survival - Session Highlights May 16, 2011

AUA 2011 - Inhibition of prostate cancer progression by dutasteride and the impact on anxiety, quality of life, and urinary symptoms in men undergoing active surveillance: REDEEM study results - Session Highlights May 16, 2011

AUA 2011 - Interleukin-6: A potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer - Session Highlights May 16, 2011

AUA 2011 - John Duckett Memorial Lecture: Urology in 2040 - what will it look like? - Session Highlights May 16, 2011

AUA 2011 - Long term results of immediate versus deferred androgen deprivation in patients with no local treatment for T0-4 N0-2 M0 prostate cancer (EORTC 30891) - Session Highlights May 16, 2011

AUA 2011 - Meat and related meat mutagen consumption and risk of advanced prostate cancer - Session Highlights May 16, 2011

AUA 2011 - Neuropeptides promote castration resistant prostate cancer through intracrine androgen biosynthesis - Session Highlights May 16, 2011

AUA 2011 - Panel discussion: Conflicting guidelines for the treatment of vesicoureteral reflux - Session Highlights May 16, 2011

AUA 2011 - Pediatrics: Andrology – cryptorchidism and varicoceles - Session Highlights May 16, 2011

AUA 2011 - Phase 1-2 study of MDV3100 in pre-and post-docetaxel advanced prostate cancer: long-term efficacy results - Session Highlights May 16, 2011

AUA 2011 - Pre-operative urinary prostate cancer gene 3 (PCA3) is predicting pathologically confirmed small volume and insignificant prostate cancer - Session Highlights May 16, 2011

Page 587 of 594